dm+d
Unassigned
New Medicines
Skin and skin structure infections; acute bacterial skin and skin structure infections (ABSSSI)
Information
New molecular entity
Not Known
MicuRx Pharmaceuticals
Development and Regulatory status
None
None
Phase II Clinical Trials
Category
Oxazolidinone - ribosomal protein inhibitors
9 September 2020In England in 2018/19, there were ~241,000 finished consultant episodes of skin infections including cellulitis, local infections of skin tissues and cutaneous abscess. Up to 10% receive targeted antimicrobial therapy based on antibiotic resistance rates (~40 per 100,000 people), rather than empirical therapy. [7]
Skin and skin structure infections; acute bacterial skin and skin structure infections (ABSSSI)
Oral